Mobia Medical, Inc. IPO - What You Need to Know

Thinking about jumping into the Mobia Medical IPO? It is exciting to get in on the ground floor, but before you invest, let’s break down the facts in plain English.

1. What does this company actually do?

Mobia Medical is a health-tech company focused on chronic stroke recovery. Their Vivistim System is an FDA-approved, implantable device that helps stroke survivors regain arm and hand movement.

Think of it as a "brain trainer." By sending gentle pulses to the vagus nerve during physical therapy, it helps the brain "rewire" itself. This process is called Paired Vagus Nerve Stimulation. It has shown success in patients even decades after their stroke. The procedure is a 60-minute outpatient surgery, and patients typically go home the same day. The system includes an implanted pulse generator, a lead wire, and a wireless transmitter that therapists use during rehabilitation.

2. How are they performing financially?

Mobia is growing quickly, but they are burning through cash to do it.

• The Good News: Revenue is climbing. They brought in $32 million in 2025, more than double the $15.6 million they made in 2024. This money comes primarily from selling Vivistim hardware kits to hospitals.
• The Bad News: They spend much more than they make. In 2025, they lost $46.5 million, up from a $24.6 million loss the year before. Most of this money goes toward sales, marketing, and research. They are heavily investing in a larger sales team and new clinical studies to convince more doctors to use their device.

3. What’s the catch with insurance?

This is their biggest hurdle. Getting insurance companies to pay for this specialized treatment is a constant battle. Their long-term success depends on proving to insurers that this treatment is a standard, cost-effective necessity. Currently, many insurance providers deny claims for the Vivistim System. This forces patients to pay out-of-pocket or skip the procedure. Without widespread insurance coverage, the company will struggle to grow its revenue.

4. What are the main risks?

• "Going Concern" Warning: The company warns that their losses raise "substantial doubt" about their ability to stay in business. Simply put: they rely on raising more money just to keep the lights on. If they cannot raise enough, they might shut down, and investors could lose everything.
• Single-Product Reliance: Their entire business depends on the Vivistim System. If they cannot market this one product successfully, or if a competitor releases something better, they have no backup plan.
• Growing Pains: Doubling revenue in a year is impressive, but it strains their team and inventory management. Growing too fast without the right systems could lead to expensive mistakes in their supply chain or regulatory compliance.

5. Who's running the company?

CEO Richard Foust leads the company from Austin, Texas. The team is currently focused on building the infrastructure needed to support the Vivistim System across the United States.

6. Where will it trade?

Mobia Medical plans to list on the NASDAQ exchange under the ticker symbol "MOBI."

I am an AI, not a financial advisor. IPOs are volatile. The company warns they are losing money and face significant hurdles. Never invest money you cannot afford to lose, and always read the official "Prospectus" on the SEC website before you buy!